<DOC>
	<DOCNO>NCT02328547</DOCNO>
	<brief_summary>The objective study ( 1 ) determine efficacy fecal microbiota transplantation ( FMT ) , give oral capsule , compare placebo treatment refractory diarrhea-predominant irritable bowel syndrome ( IBS-D ) ; ( 2 ) determine impact FMT intestinal microbiome patient IBS-D ; ( 3 ) ass safety , feasibility , tolerability FMT patient IBS-D .</brief_summary>
	<brief_title>Fecal Microbiota Transplantation Treatment Diarrhea-Predominant Irritable Bowel Syndrome</brief_title>
	<detailed_description>This multicenter study include Montefiore Medical Center , Concorde Medical Group PLLC Medical Research Center Connecticut/Yale-New Haven Hospital Langone Medical Center . Patients IBS-D recruited outpatient gastroenterology clinic institution referral medical community . FMT capsule placebo capsule , provide OpenBiome , Medford , MA , use study . Patients randomize undergo FMT use fecal capsule ( experimental group ) placebo capsule ( control group ) via computer-generated program . All patient cross-over alternate arm study 12 week . Therefore , patient enrol receive experimental drug course study . Each patient enrol study total 6 month . Intestinal microbiome analysis use DNA sequence non-cultivation-based approach ( 16S DNA technology ) perform patient experimental control group assess stability microbiome time .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>age 1965 year establish diagnosis IBSD determine Rome III Criteria moderatesevere disease activity ( determine IBSSymptom Severity Score â‰¥175 ) persistent symptom despite conventional therapy normal colonoscopy biopsy past workup IBS symptom negative workup celiac disease either duodenal biopsy negative serology pregnancy nurse cognitive impairment severe neuropsychiatric comorbidities incapable provide informed consent severely immunocompromised immunosuppressed patient ( e.g. , organ transplant recipient , severe neutropenia absolute neutrophil count &lt; 500cells/mL , current treatment treatment within 3 month antineoplastic agent HIVpositive patient CD4 count &lt; 200cells/mm^3 ) treat antibiotic 3 month prior FMT GI symptom explain presence underlie organic disease include , underlie inflammatory bowel disease , infectious enteritis , previously establish untreated small intestinal bacterial overgrowth know motility disorder previous FMT severe ( anaphylactic ) food allergy unable comply protocol requirement American Society Anesthesiologists ( ASA ) Physical Status classification IV V acute illness fever day plan FMT exclude ( randomize ) option include subject future date new antidepressant start dose antidepressant change &lt; 3 month prior enrollment elevate ESR CRP within past 3 month baseline laboratory abnormality CBC , chemistry liver test pain score &gt; 75 IBSSSS</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>fecal microbiota transplantation</keyword>
	<keyword>diarrhea-predominant</keyword>
</DOC>